Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Abstract: Systems, methods and media for testing computer programs in response to a program upgrade or installation are disclosed. In one embodiment, a computer executes software to detect when an upgrade or an installation occurs. When an upgrade or installation occurs the computer initiates a test of one or more applications and/or operating systems. The results of these tests are logged in one or more error logs that can be displayed to a program developer or operating system administrator for diagnosis.

Abstract: Described is a parallel batch reactor for effecting chemical reactions. The parallel batch reactor includes a plurality of reactor vessels for receiving components of a reaction, an inlet port for receiving pressurized fluid, and a plurality of valves configured to transfer fluid from the inlet port to the reactor vessels and fluidically isolate one or more of the reactor vessels from at least one of the other reactor vessels. The reactor further includes a pressure monitoring system comprising an array of pressure sensors configured to sense pressure in the reactor vessels. Each of the pressure sensors is aligned with one of the plurality of reactor vessels and located external to the reactor vessels and fluid passageways in fluid communication with the reactor vessels.

Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Abstract: A conveyor system is disclosed herein. An embodiment of the conveyor system comprises a first end, a second end, a first side, and a second side. A belt extends between the first end and the second end. The belt has a belt first side located proximate the first side of the conveyor. A first magnetic force acts on the belt first side relative to the first side of the conveyor.

Abstract: A reactor system includes a housing and a plurality of reactors at least partially contained in the housing. The reactors each have a containment structure enclosing an internal space in the reactor. The containment structure including a circumferential sidewall having opposite ends and surrounding at least a portion of said internal space. The sidewall has a thermal mass and a sidewall heater adjacent an exterior surface of the sidewall. The ratio of the thermal mass of the sidewall to a volume of the portion of the internal space that is surrounded by the sidewall is relatively low.

Abstract: A conveyor is disclosed herein. An embodiment of the conveyor comprises an upper side, an under side, a first end, a second end, and a frame comprising a first side and a second side. At least one roller is located in the underside, the at least one roller extends between the frame first side and the frame second side. A belt extends between the first end and the second end, wherein the belt contacts the at least one roller. A bracket connects the first side of the frame to the at least one roller. The bracket comprises a first portion that is pivotally connected to the first side of the frame and a second portion pivotally connected to the roller, the bracket enables the roller to pivot relative to the first side of the frame.

Abstract: A ball transfer device is disclosed herein. An embodiment of the ball transfer device includes a chamber, a first ball, and a second ball. A first opening and a second opening extend into the chamber. A cavity extends from the chamber and has a cavity opening connected to the second opening. The first ball is movable within the chamber between a first position and a second position, wherein a portion of the first ball is movable into the first opening when the first ball is in the first position, and wherein the first ball is located between the first opening and the second opening. The second ball is located in the cavity, wherein the second ball is movable within the cavity between a first position and a second position, wherein a portion of the second ball is movable into the chamber when the second ball is in the first position, and wherein the first ball is located between the cavity and the cavity opening. The second ball is contactable with the first ball when the second ball is in the first position.

Abstract: In one embodiment, a parallel batch reactor generally includes a plurality of reactor vessels and a plurality of valves configured to allow flow into the reactor vessels when a gas is supplied to the reactor at a pressure higher than a pressure within the reactor vessels and restrict flow from the reactor vessels. A method includes inserting chemical components into the reactor vessels, supplying a first gas to the reactor vessels to pressurize the reactor vessels, stopping supply of the first gas, and supplying a second gas to the reactor at a lower pressure than a pressure within the reactor vessels. The second gas passes through the valves and into the reactor vessels when the pressure within the reactor vessels drops below the pressure of the second gas.

Abstract: Cell specific replication-competent viral vectors comprising a self processing peptide cleavage sequence are provided. The targeted replication-competent viral vectors include two or more co-transcribed genes under transcriptional control of the same heterologous transcriptional regulatory element (TRE), wherein at least a second gene is under translational control of a self processing cleavage sequence or 2A sequence. Exemplary vector constructs may further include an additional proteolytic cleavage site which provides a means to remove the self processing peptide sequence from the viral vector.

Abstract: Conveyor diverters are disclosed herein. One embodiment of a conveyor diverter comprises an arm comprising a first end and a second end. The arm has a first surface extending between a location proximate the first end and a location proximate the second end. The arm is movable between a first position and a second position. A chain is located within the arm. The chain comprises at least one roller assembly, wherein at least a portion of the roller assembly extends beyond the first surface.

Abstract: A conveyor for moving items in a direction is disclosed herein. The conveyor may comprise a first end and a second end, wherein the second end is not perpendicular to the direction. A first pulley and a second pulley may be located proximate the second end with a connector connecting the first pulley to the second pulley. A first belt extends between the first end and the first pulley. A second belt extends between the first end and the second pulley. The second belt is longer than the first belt.